Home  |  Contact

UniProtKB/Swiss-Prot Q8WXH0: Variant p.Thr6211Met

Nesprin-2
Gene: SYNE2
Variant information

Variant position:  6211
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Threonine (T) to Methionine (M) at position 6211 (T6211M, p.Thr6211Met).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to medium size and hydrophobic (M)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In EDMD5.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  6211
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  6885
The length of the canonical sequence.

Location on the sequence:   TQLELINKQYRRLARENRTD  T ASRLKQMVHEGNQRWDNLQR
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         TQLELINKQYRRLARENRTDTASRLKQMVHEGNQRWDNLQR

Mouse                         TQLELINKQYRRLARENRTDTASKLKQMVHEGNQRWDNLQK

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 6885 Nesprin-2
Topological domain 1 – 6834 Cytoplasmic
Repeat 6136 – 6243 Spectrin 52
Coiled coil 297 – 6782
Alternative sequence 1 – 6469 Missing. In isoform 6.
Alternative sequence 1 – 6434 Missing. In isoform 11.
Alternative sequence 1 – 6366 Missing. In isoform 5 and isoform 12.
Alternative sequence 1 – 6217 Missing. In isoform 10.
Alternative sequence 268 – 6885 Missing. In isoform 9.
Alternative sequence 286 – 6885 Missing. In isoform 8.


Literature citations

Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity.
Zhang Q.; Bethmann C.; Worth N.F.; Davies J.D.; Wasner C.; Feuer A.; Ragnauth C.D.; Yi Q.; Mellad J.A.; Warren D.T.; Wheeler M.A.; Ellis J.A.; Skepper J.N.; Vorgerd M.; Schlotter-Weigel B.; Weissberg P.L.; Roberts R.G.; Wehnert M.; Shanahan C.M.;
Hum. Mol. Genet. 16:2816-2833(2007)
Cited for: VARIANT EDMD5 MET-6211;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.